{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:03:37Z","timestamp":1790456617607,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijrobp.2025.03.053","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:37:09Z","timestamp":1743899829000},"page":"195-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Randomized Comparison of High-Dose-Rate and Low-Dose-Rate Prostate Brachytherapy Combined With External Beam Radiation Therapy for Unfavorable Prostate Cancer: Efficacy Results After Median Follow-up of 74 Months"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0711-3318","authenticated-orcid":false,"given":"Juanita","family":"Crook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Chi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Arbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deidre","family":"Batchelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Bachand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.03.053_bib0001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0002","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0007","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2024.02.064","article-title":"A randomized trial comparing quality of life after low-dose rate or high-dose rate prostate brachytherapy boost with pelvic external beam radiation therapy","volume":"120","author":"Crook","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brachy.2005.12.002","article-title":"Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy","volume":"5","author":"Martens","year":"2006","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0003","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cncr.23139","article-title":"The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer","volume":"112","author":"Abramowitz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.brachy.2012.05.001","article-title":"Implications of CT imaging for postplan quality assessment in prostate brachytherapy","volume":"11","author":"Petrik","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0006","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","article-title":"A biochemical definition of cure after brachytherapy for prostate cancer","volume":"149","author":"Crook","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ijrobp.2025.03.053_bib0008","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0009","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy."},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0011","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0012","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0013","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijrobp.2007.09.020","article-title":"Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer","volume":"71","author":"Kupelian","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0015","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0016","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven International Institutional Datasets: \u03b1\/\u03b2 = 1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0017","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0360-3016(01)01594-2","article-title":"Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer","volume":"51","author":"Merrick","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0018","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.ijrobp.2016.12.014","volume":"97","author":"Ciezki","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0019","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bju.14122","article-title":"Low-dose-rate brachytherapy for prostate cancer: Outcomes at >10 years of follow-up","volume":"121","author":"Lazarev","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0020","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.urology.2004.04.054","article-title":"Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer","volume":"64","author":"Merrick","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0021","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5114\/jcb.2021.105280","article-title":"Low-\/high-dose-rate brachytherapy boost in patients with intermediate-risk prostate cancer treated with radiotherapy: Long-term results from a single institution team experience","volume":"13","author":"Villalba","year":"2021","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0023","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10147-023-02314-0","article-title":"Comparison of outcomes in high-risk prostate cancer patients treated with low-\/high-dose-rate brachytherapy plus external beam radiotherapy","volume":"28","author":"Imai","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0024","first-page":"1","article-title":"A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy","volume":"20","author":"Slevin","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brachy.2018.12.007","article-title":"A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer","volume":"18","author":"King","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0026","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0027","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0028","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0029","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41391-019-0185-7","article-title":"Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy","volume":"23","author":"Marascio","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2025.03.053_bib0031","doi-asserted-by":"crossref","first-page":"506","DOI":"10.6004\/jnccn.2019.7306","article-title":"Current status of MRI and PET in the NCCN guidelines for prostate cancer","volume":"17","author":"Mason","year":"2019","journal-title":"J Natl Compr Canc Netw"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625003037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625003037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:33:42Z","timestamp":1777955622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625003037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0360301625003037"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.053","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Comparison of High-Dose-Rate and Low-Dose-Rate Prostate Brachytherapy Combined With External Beam Radiation Therapy for Unfavorable Prostate Cancer: Efficacy Results After Median Follow-up of 74 Months","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}